TRCT
NMTC icon

Tower Research Capital (TRC)’s NeuroOne Medical Technologies NMTC Stock Holding History

Tower Research Capital (TRC)’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-775
Closed -$3.52K – 5409
2025
Q4 		$3.52K Buy
775
+146
+23% +$665 ﹤0.01% 4358
2025
Q3 		$3.35K Sell
629
-809
-56% -$3.96K ﹤0.01% 4515
2025
Q2 		$5.85K Buy
+1,438
New +$5.31K ﹤0.01% 4145
2025
Q1 		– Sell
-958
Closed -$4.75K – 5600
2024
Q4 		$4.75K Buy
958
+234
+32% +$1.17K ﹤0.01% 4404
2024
Q3 		$4.3K Sell
724
-1,177
-62% -$5.89K ﹤0.01% 4593
2024
Q2 		$9.12K Buy
1,901
+734
+63% +$4.61K ﹤0.01% 4286
2024
Q1 		$8.4K Buy
1,167
+311
+36% +$2.35K ﹤0.01% 4025
2023
Q4 		$8.12K Buy
+856
New +$6.31K ﹤0.01% 4542
2023
Q3 		– Sell
-1,706
Closed -$12.3K – 6141
2023
Q2 		$12.3K Buy
1,706
+806
+90% +$6.53K ﹤0.01% 3888
2023
Q1 		$8K Buy
900
+217
+32% +$2.01K ﹤0.01% 4645
2022
Q4 		$5K Sell
683
-225
-25% -$2.01K ﹤0.01% 4887
2022
Q3 		$9K Buy
908
+7
+0.8% +$67 ﹤0.01% 4671
2022
Q2 		$4K Buy
+901
New +$5.01K ﹤0.01% 5235
2022
Q1 		– Sell
-48
Closed -$1K – 6413
2021
Q4 		$1K Sell
48
-770
-94% -$12.5K ﹤0.01% 5864
2021
Q3 		$20K Buy
+818
New +$23.5K ﹤0.01% 3715

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Tower Research Capital (TRC)'s NMTC Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of NeuroOne Medical Technologies (NMTC) in Q1 2026, closing a stake of 775 shares — an estimated $3.52K sold.

Tower Research Capital (TRC) first reported a position in NMTC in Q3 2021 and held it in 15 quarters. The position peaked at $20K in Q3 2021. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining NeuroOne Medical Technologies position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 775 NeuroOne Medical Technologies shares in Q1 2026, an estimated $3.52K.
  • Tower Research Capital (TRC) first reported a position in NeuroOne Medical Technologies in Q3 2021 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s NeuroOne Medical Technologies position peaked at $20K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.